JP2010523477A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010523477A5 JP2010523477A5 JP2009554735A JP2009554735A JP2010523477A5 JP 2010523477 A5 JP2010523477 A5 JP 2010523477A5 JP 2009554735 A JP2009554735 A JP 2009554735A JP 2009554735 A JP2009554735 A JP 2009554735A JP 2010523477 A5 JP2010523477 A5 JP 2010523477A5
- Authority
- JP
- Japan
- Prior art keywords
- carbonyl
- amino acid
- aryl
- side chain
- arylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 36
- -1 5-tetrazolyl Chemical group 0.000 claims 15
- 125000003545 alkoxy group Chemical group 0.000 claims 12
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims 12
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 12
- 125000001769 aryl amino group Chemical group 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 12
- 125000004104 aryloxy group Chemical group 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000003282 alkyl amino group Chemical group 0.000 claims 10
- 239000003112 inhibitor Substances 0.000 claims 10
- 125000003342 alkenyl group Chemical group 0.000 claims 9
- 150000001413 amino acids Chemical class 0.000 claims 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 125000002252 acyl group Chemical group 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 8
- 150000008574 D-amino acids Chemical group 0.000 claims 6
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 6
- 125000004414 alkyl thio group Chemical group 0.000 claims 6
- 125000004659 aryl alkyl thio group Chemical group 0.000 claims 6
- 125000005110 aryl thio group Chemical group 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- DYMRYCZRMAHYKE-UHFFFAOYSA-N n-diazonitramide Chemical compound [O-][N+](=O)N=[N+]=[N-] DYMRYCZRMAHYKE-UHFFFAOYSA-N 0.000 claims 6
- 125000006239 protecting group Chemical group 0.000 claims 6
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 claims 6
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 6
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 150000008575 L-amino acids Chemical group 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 241000283690 Bos taurus Species 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 241000283086 Equidae Species 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000008999 Giant Cell Carcinoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 241000282887 Suidae Species 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 206010006007 bone sarcoma Diseases 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000000762 glandular Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 201000000014 lung giant cell carcinoma Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 0 CCCCN([C@](C)*)C(C(C)(*)NN)=* Chemical compound CCCCN([C@](C)*)C(C(C)(*)NN)=* 0.000 description 3
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89578707P | 2007-03-20 | 2007-03-20 | |
| PCT/US2008/057636 WO2008116054A1 (en) | 2007-03-20 | 2008-03-20 | Inhibitors of fibroblast activation protein, and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010523477A JP2010523477A (ja) | 2010-07-15 |
| JP2010523477A5 true JP2010523477A5 (OSRAM) | 2011-05-12 |
Family
ID=39766448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009554735A Abandoned JP2010523477A (ja) | 2007-03-20 | 2008-03-20 | 線維芽細胞活性化タンパク質の阻害剤、およびそれを使用する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20100105753A1 (OSRAM) |
| EP (1) | EP2139337A4 (OSRAM) |
| JP (1) | JP2010523477A (OSRAM) |
| AU (1) | AU2008228863A1 (OSRAM) |
| CA (1) | CA2681351A1 (OSRAM) |
| WO (1) | WO2008116054A1 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010083570A1 (en) * | 2009-01-23 | 2010-07-29 | The University Of Sydney | Novel metabolic disease therapy |
| BR112013010372A2 (pt) * | 2010-12-14 | 2016-07-05 | Merck Sharp & Dohme | composto, e, método para preparar um composto |
| CN108383893A (zh) * | 2011-08-30 | 2018-08-10 | 塔夫茨大学信托人 | 用于治疗实体瘤的fap-活化的蛋白酶体抑制剂 |
| CA2856379A1 (en) * | 2011-11-22 | 2013-05-30 | Trustees Of Tufts College | Small molecule enhancer for dendritic cell cancer vaccines |
| CN116474108A (zh) | 2016-12-14 | 2023-07-25 | 普渡研究基金会 | 成纤维细胞活化蛋白(fap)-靶向成像和治疗 |
| SI3997103T1 (sl) | 2019-07-08 | 2025-04-30 | 3B Pharmaceuticals Gmbh | Spojine, ki obsegajo ligand proteina za aktiviranje fibroblastov in uporaba le teh |
| CN118930608A (zh) | 2019-07-08 | 2024-11-12 | 3B制药有限公司 | 包含成纤维细胞活化蛋白配体的化合物及其用途 |
| EP3763726A1 (en) | 2019-07-08 | 2021-01-13 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| CN115943312A (zh) | 2020-05-07 | 2023-04-07 | 法国居里学院 | 免疫抑制性成纤维细胞群体的生物标志物antxr1及其在预测对免疫疗法的反应中的用途 |
| EP4050018A1 (en) | 2021-01-07 | 2022-08-31 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| CA3206863A1 (en) | 2021-01-07 | 2022-07-14 | 3B Pharmaceuticals Gmbh | Compounds comprising a fibroblast activation protein ligand and use thereof |
| CN114316136B (zh) * | 2022-01-13 | 2023-01-31 | 西华师范大学 | 一种氢键增强型水合物抑制剂及其制备方法 |
| AU2023329434A1 (en) * | 2022-08-25 | 2025-02-20 | The Regents Of The University Of California | Fibroblast activation protein alpha-cleavable pro-peptides and methods of use |
| WO2025046043A1 (en) | 2023-08-31 | 2025-03-06 | Stichting Radboud Universitair Medisch Centrum | Endometriosis tracer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE04029691T1 (de) * | 1998-02-02 | 2007-11-08 | Trustees Of Tufts College, Medford | Verwendung von Dipetidylpeptidasehemmer zur Regulierung des Glukosemetabolismus |
| US6890904B1 (en) * | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
| US7041696B2 (en) * | 2002-06-17 | 2006-05-09 | The Procter & Gamble Company | Interleukin-1β converting enzyme inhibitors |
| CA2633803A1 (en) * | 2005-12-19 | 2007-09-07 | Trustees Of Tufts College | Soft protease inhibitors and pro-soft forms thereof |
-
2008
- 2008-03-20 EP EP08732547A patent/EP2139337A4/en not_active Withdrawn
- 2008-03-20 US US12/532,274 patent/US20100105753A1/en not_active Abandoned
- 2008-03-20 JP JP2009554735A patent/JP2010523477A/ja not_active Abandoned
- 2008-03-20 CA CA002681351A patent/CA2681351A1/en not_active Abandoned
- 2008-03-20 WO PCT/US2008/057636 patent/WO2008116054A1/en not_active Ceased
- 2008-03-20 AU AU2008228863A patent/AU2008228863A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010523477A5 (OSRAM) | ||
| JP2005525345A5 (OSRAM) | ||
| JP2019510832A5 (OSRAM) | ||
| RU2009138500A (ru) | 4, -о-замещенные изоиндолиновые производные и содержащие их композиции и способы их применения | |
| JP2001247459A5 (OSRAM) | ||
| JP2019503365A5 (OSRAM) | ||
| JP2015517523A5 (OSRAM) | ||
| JP2009524675A5 (OSRAM) | ||
| JP2015517976A5 (OSRAM) | ||
| RU2006109467A (ru) | Способы лечения рака с использованием ингибиторов hdac | |
| ES2946472T3 (es) | Agente antitumoral y potenciador del efecto antitumoral | |
| RU2014111069A (ru) | Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение | |
| JP2004517099A5 (OSRAM) | ||
| RU2009117388A (ru) | Моногидрат 4-[4-({[4-хлор-3-(трифторметил)фенил]карбамоил})амино)-3-фторфенокси]-n-метилпиридин-2-карбоксамида | |
| CY1114803T1 (el) | Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης | |
| MEP10808A (en) | Solid drug for oral use | |
| JP2015536986A5 (OSRAM) | ||
| RU2016122731A (ru) | Функционализированные и замещенные индолы в качестве противораковых агентов | |
| CY1108061T1 (el) | Παραγωγα κιναζολινης ως src αναστολεις κινασης τυροσινης | |
| RU2008139195A (ru) | Замещенные арилсульфанамиды как противовирусные средства | |
| JP2015131865A (ja) | 抗癌用医薬 | |
| JP2017532316A5 (OSRAM) | ||
| JP2014512355A5 (OSRAM) | ||
| DE60237993D1 (de) | Derivate von isoindigo, indigo und indirubin und deren verwendung bei der behandlung von krebs | |
| ES2631879T3 (es) | Uso de pimobendano para el tratamiento de la insuficiencia cardíaca asintomática (oculta) |